Structure-based macrocyclization yields hepatitis C virus NS5B inhibitors with improved binding affinities and pharmacokinetic properties.
Cummings, M.D., Lin, T.I., Hu, L., Tahri, A., McGowan, D., Amssoms, K., Last, S., Devogelaere, B., Rouan, M.C., Vijgen, L., Berke, J.M., Dehertogh, P., Fransen, E., Cleiren, E., van der Helm, L., Fanning, G., Van Emelen, K., Nyanguile, O., Simmen, K., Raboisson, P., Vendeville, S.(2012) Angew Chem Int Ed Engl 51: 4637-4640
- PubMed: 22473861 
- DOI: https://doi.org/10.1002/anie.201200110
- Primary Citation of Related Structures:  
4DRU
Organizational Affiliation: 
Janssen Infectious Diseases BVBA, Turnhoutseweg 30, 2340 Beerse, Belgium. mcummin1@its.jnj.com